Heron Therapeuti (HRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $59.08M
Last updated: Nov 17, 2026 at 4:41 PM ET
Heron Therapeuti (HRTX) Statistics
Heron Therapeuti (HRTX) has a market cap of $59.08M and an enterprise value of $173.50M. Its share count is up 12.08% from a year earlier. Its net debt of $114.42M equals 193.66% of its market cap.
Total Valuation
Enterprise value is 193.66% above the market cap, as debt exceeds cash.
| Market Cap | $59.08M |
|---|---|
| Enterprise Value | $173.50M |
| Latest price (Nov 17, 2026) | $0.28 |
Key Dates
| Last Earnings Date | Nov 9, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.4x and 13.9x. Its year-end P/S ranged from 1.4x to 402.3x from 2016 to 2025.
| P/S Ratio | 0.4x |
|---|---|
| Forward P/S | 0.4x |
| P/B Ratio | 13.9x |
Price Statistics
The stock is down 74.35% over 52 weeks and trades 15.15% below its 50-day average.
| Beta (1Y) | 2.05 |
|---|---|
| 52-Week Change | -74.35% |
| 1-Month Change | -21.81% |
| 3-Month Change | -10.38% |
| 6-Month Change | -66.73% |
| 5-Year Change | -97.48% |
| 10-Year Change | -98.13% |
| Total Return (1Y) | -74.35% |
| Total Return (3Y CAGR) | -36.26% |
| Total Return (5Y CAGR) | -51.56% |
| Max Drawdown (1Y) | -81.88% |
| Max Drawdown (3Y) | -93.01% |
| Sharpe Ratio (1Y) | -1.30 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $0.33 |
| 200-Day Average | $0.63 |
| 52-Week Range | $0.26 to $1.57 |
| RSI (14 Days) | 42.0 |
| Average Volume (20 Days) | 9.70M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.33x current liabilities, and total debt is 25.63x shareholder equity.
| Current Ratio | 2.33x |
|---|---|
| Quick Ratio | 1.31x |
| Debt / Equity | 25.63x |
Returns and Efficiency
Return on invested capital is -8.39% over the last 12 months, against a 5-year average of -0.61%.
| Return on Equity (ROE) | -438.57% |
|---|---|
| Return on Assets (ROA) | -9.36% |
| Return on Invested Capital (ROIC) | -8.39% |
| Return on Capital Employed (ROCE) | -9.89% |
| ROA (5Y Average) | -41.63% |
| ROIC (5Y Average) | -0.61% |
| Asset Turnover | 0.62x |
| Inventory Turnover | 0.46x |
| Receivables Turnover | 1.68x |
| Cash Conversion Cycle | 916 days |
Scores
HRTX has an Altman Z-Score of -10.69, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -10.69 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $148.22M over the last 12 months is down 4.44% from the 12 months before.
| Revenue | $148.22M |
|---|---|
| Revenue Growth (YoY) | -4.44% |
| Gross Profit | $105.93M |
| Operating Income | -$8.44M |
| Pretax Income | -$21.56M |
| Net Income | -$21.56M |
| EBIT | -$13.90M |
| Reported EPS (TTM) | -$0.12 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 2.13% of the $230.45M in total assets.
| Cash and Equivalents | $11.60M |
|---|---|
| Total Debt | $126.01M |
| Net Debt | $114.42M |
| Net Debt Per Share | $0.60 |
| Working Capital | $119.26M |
| Shareholder Equity | $4.92M |
| Book Value Per Share | $0.02 |
| Total Assets | $230.45M |
| Total Liabilities | $225.53M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $631.00K of capital spending, operating cash flow left -$14.36M of free cash flow.
| Operating Cash Flow | -$13.73M |
|---|---|
| Capital Expenditures | $631.00K |
| Free Cash Flow | -$14.36M |
| FCF Per Share | -$0.08 |
| Depreciation and Amortization | $2.35M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -5.69%.
| Gross Margin | 71.47% |
|---|---|
| Operating Margin | -5.69% |
| Pretax Margin | -14.55% |
| Net Margin | -14.55% |
| EBIT Margin | -9.38% |
| FCF Margin | -9.69% |
| Gross Margin (5Y Average) | 58.20% |
Growth
Revenue grew 12.89% a year over 3 years.
| Revenue Growth (3Y CAGR) | +12.89% |
|---|---|
| Revenue Growth (5Y CAGR) | +11.81% |
Dividends and Yields
HRTX does not pay a dividend.
| Buyback Yield | 2.35% |
|---|---|
| Shareholder Yield | 2.35% |
Stock Splits
The last split was a 1-for-20 reverse split on Jan 13, 2014.
| Last Split Date | Jan 13, 2014 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 7 similar companies, HRTX has the lowest P/S.
P/S RatioPeer median 2.4x
ROICPeer median -112.79%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.12%
| P/S Ratio | 0.4x vs 2.4x median |
|---|---|
| ROIC | -8.39% vs -112.79% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -4.44% vs +5.12% median |
Analyst Forecast
Consensus estimates put revenue growth at -4.80% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -4.80% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About HRTX
What is HRTX's market cap?
Heron Therapeuti has a market cap of $59.08M. Its enterprise value, which adds debt and subtracts cash, is $173.50M.
How many shares of HRTX are outstanding?
Heron Therapeuti has 190.92M shares outstanding. The count is up 12.08% from a year earlier.
Does HRTX pay a dividend?
No. Heron Therapeuti does not pay a dividend.
How much debt does HRTX have?
Heron Therapeuti has $126.01M of total debt and $11.60M of cash and equivalents, a net debt position of $114.42M.
HRTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors